Open AccessNuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients
Author(s) -
Ji Eun Park,
Mi Jeong Hong,
Shin Yup Lee,
Jang Hyuck Lee,
Jin Eun Choi,
Hyunwoo Kang,
Sook Kyung,
Ji Yun Jeong,
Kyung Min Shin,
Won Kee Lee,
Sun Ha Choi,
Yong Hoon Lee,
Hogyun Seo,
Seung Soo Yoo,
Jaehee Lee,
Seung Ick,
Chang Ho Kim,
Jae Yong Park
Publication year - 2021
Publication title -
pharmacogenomics and personalized medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.845
H-Index - 28
ISSN - 1178-7066
DOI - 10.2147/pgpm.s329055
Subject(s) - medicine , tyrosine kinase , epidermal growth factor receptor , cancer research , receptor tyrosine kinase , lung , adenocarcinoma , receptor , oncology , cancer
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have represented the prototype of targeted therapy in NSCLC. Patients with EGFR-mutant lung adenocarcinoma extract an extraordinary clinical benefit from EGFR-TKIs. However, the extent and duration of these responses are heterogeneous, suggesting the existence of genetic modifiers affecting an individual's response to TKIs. We investigated whether genetic variants in miRNA binding sites are associated with the clinical outcome of EGFR-TKIs in lung adenocarcinoma patients.